Kevin Robert Reylado
Primary Care · North Arlington, NJNPI 1619650702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 24.0% of the total. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Novo Nordisk$661
- Sanofi$625
- Boehringer Ingelheim$583
- Lilly USA, LLC$462
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,17398%
- Education$1712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $2,004 |
| GSK | 30 | $1,281 |
| Novo Nordisk | 44 | $661 |
| Sanofi | 20 | $625 |
| Boehringer Ingelheim | 16 | $583 |
| Lilly USA, LLC | 17 | $462 |
| Axsome Therapeutics, Inc. | 16 | $404 |
| Intra-sana Laboratories | 3 | $258 |
| Xeris Pharmaceuticals, Inc. | 7 | $215 |
| Otsuka America Pharmaceutical, Inc. | 5 | $188 |
| Idorsia Pharmaceuticals US Inc | 13 | $188 |
| Sanofi-aventis U.S. LLC | 3 | $185 |
| Exact Sciences | 7 | $145 |
| Johnson & Johnson | 2 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $103 |
| Pfizer | 6 | $99 |
| Lundbeck LLC | 5 | $91 |
| Almatica Pharma LLC | 6 | $90 |
| ANI Pharmaceuticals, Inc. | 5 | $73 |
| Mallinckrodt Hospital Products Inc. | 4 | $66 |
| Amgen | 4 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Azurity Pharmaceuticals, Inc. | 2 | $33 |
| Baxter Healthcare | 2 | $33 |
| Inogen, Inc. | 2 | $32 |
| Boston Scientific | 1 | $26 |
| Mylan Specialty L.p. | 1 | $19 |
| Biotronik NRO, Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,344 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $48,910 |
| OzempicSemaglutide | 30 | $33,789 |
| MounjaroTirzepatide | 22 | $24,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,609 |
| XareltoRivaroxaban | 19 | $18,585 |
| JanuviaSitagliptin Phosphate | 11 | $13,532 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $10,094 |
| FarxigaDapagliflozin Propanediol | 12 | $10,052 |
| LinzessLinaclotide | 12 | $6,005 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $2,709 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,511 |
| Olmesartan Medoxomil | 16 | $2,177 |
| Fluticasone Propionate | 73 | $1,862 |
| Atorvastatin Calcium | 143 | $1,807 |
| Rosuvastatin Calcium | 87 | $1,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $583 | $48,91048 claims |
| Novo NordiskOzempic | $661 | $33,78930 claims |
| Lilly USA, LLCMounjaro | $462 | $24,37422 claims |
| GSKTrelegy Ellipta | $1,281 | $20,60927 claims |
| Johnson & JohnsonXarelto | $143 | $18,58519 claims |
| AstraZenecaFarxiga | $2,004 | $10,05212 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $185 | $2,70916 claims |
| PfizerPaxlovid | $99 | $1,42919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.
Other primary care in North Arlington
- Tanya VilchezNorth Arlington$3K
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.